DrugPatentWatch Database Preview
PROCYSBI Drug Profile
When do Procysbi patents expire, and what generic alternatives are available?
Procysbi is a drug marketed by Horizon Pharma Usa and is included in one NDA. There are eight patents protecting this drug.
This drug has thirty-five patent family members in twenty-five countries.
The generic ingredient in PROCYSBI is cysteamine bitartrate. There are six drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the cysteamine bitartrate profile page.
Summary for PROCYSBI
International Patents: | 35 |
US Patents: | 8 |
Applicants: | 1 |
NDAs: | 1 |
Suppliers / Packagers: | 2 |
Bulk Api Vendors: | 16 |
Patent Applications: | 89 |
Formulation / Manufacturing: | see details |
DailyMed Link: | PROCYSBI at DailyMed |

Pharmacology for PROCYSBI
Drug Class | Cystine Depleting Agent |
Mechanism of Action | Cystine Disulfide Reduction |
US Patents and Regulatory Information for PROCYSBI
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Horizon Pharma Usa | PROCYSBI | cysteamine bitartrate | CAPSULE, DELAYED RELEASE;ORAL | 203389-002 | Apr 30, 2013 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
Horizon Pharma Usa | PROCYSBI | cysteamine bitartrate | CAPSULE, DELAYED RELEASE;ORAL | 203389-002 | Apr 30, 2013 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
Horizon Pharma Usa | PROCYSBI | cysteamine bitartrate | CAPSULE, DELAYED RELEASE;ORAL | 203389-002 | Apr 30, 2013 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
Horizon Pharma Usa | PROCYSBI | cysteamine bitartrate | CAPSULE, DELAYED RELEASE;ORAL | 203389-001 | Apr 30, 2013 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
Horizon Pharma Usa | PROCYSBI | cysteamine bitartrate | CAPSULE, DELAYED RELEASE;ORAL | 203389-002 | Apr 30, 2013 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for PROCYSBI
Country | Document Number | Estimated Expiration |
---|---|---|
Hong Kong | 1218066 | ➤ Sign Up |
Mexico | 2015017366 | ➤ Sign Up |
European Patent Office | 3010491 | ➤ Sign Up |
European Patent Office | 2535044 | ➤ Sign Up |
Slovenia | 1919458 | ➤ Sign Up |
Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for PROCYSBI
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|
/2014 | Austria | ➤ Sign Up | PRODUCT NAME: CYSTEAMIN; REGISTRATION NO/DATE: EU/1/13/861/001-002 20130910 |
4 50001-2014 | Slovakia | ➤ Sign Up | PRODUCT NAME: MERKAPTAMIN; FIRST REGISTRATION: EU/1/13/861, 20130906 |
2014000023 | Germany | ➤ Sign Up | PRODUCT NAME: CYSTEAMIN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/13/861 20130906 |
2014 00013 | Denmark | ➤ Sign Up | PRODUCT NAME: CYSTEAMIN, HERUNDER MERCAPTAMINBITARTRAT; REG. NO/DATE: EU/1/13/861 20130906 |
0649 | Netherlands | ➤ Sign Up | PRODUCT NAME: CYSTEAMINE; REGISTRATION NO/DATE: EU/1/13/861/001-002 20130910 |
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |